U.S., Oct. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07207785) titled 'PirtobrUtinib as Frontline Therapy for Elderly Unfit/Frail Patient With MAntle Cell Lymphoma' on Sept. 17.
Brief Summary: This is a prospective, multicenter, phase II study, in elderly patients affected by Mantle cell lymphoma (MCL) defined as unfit/frail according to Simplified Geriatric Assessment (sGA) and previously untreated.
Patients will receive a treatment with Pirtobrutinib monotherapy until tumor progression, unacceptable adverse event, or patient decision for interruption.
Study Start Date: Feb. 01, 2026
Study Type: INTERVENTIONAL
Condition:
Mantle Cell Lymphoma
Intervention:
DRUG: Pirtobrutinib
Patients will recei...